Across TCGA pan-cancer cohorts, KBTBD12 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KBTBD12 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher KBTBD12 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KBTBD12 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and PRAD are the cancer types where KBTBD12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.079	0.733	<.001	12	view →
UCEC	DFS	Median	All	0.951	0.613	.015	10	view →
PRAD	DFS	Median	All	0.085	0.774	.007	6	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: KBTBD12 tumor-vs-normal RNA expression · all KBTBD12 data types